Zhongmei Zhou

5.4k total citations · 1 hit paper
79 papers, 4.2k citations indexed

About

Zhongmei Zhou is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Zhongmei Zhou has authored 79 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Molecular Biology, 25 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in Zhongmei Zhou's work include Kruppel-like factors research (27 papers), Cancer-related gene regulation (20 papers) and Ubiquitin and proteasome pathways (16 papers). Zhongmei Zhou is often cited by papers focused on Kruppel-like factors research (27 papers), Cancer-related gene regulation (20 papers) and Ubiquitin and proteasome pathways (16 papers). Zhongmei Zhou collaborates with scholars based in China, United States and Hong Kong. Zhongmei Zhou's co-authors include Ceshi Chen, Fadlo R. Khuri, Rong Liu, Ping Yue, Haian Fu, Shi-Yong Sun, Laura M. Rosenberg, Xuerong Wang, C Chen and Jin‐Tang Dong and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Zhongmei Zhou

77 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activation of Akt and eIF4E Survival Pathways by Rapamycin-Mediated Mammalian Target of Rapamycin Inhibition

2005 682 citations Shi-Yong Sun, Zhongmei Zhou et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zhongmei Zhou China	38	3.4k	1.1k	768	466	398	79	4.2k
Sergei Kozlov Australia	26	3.7k 1.1×	1.8k 1.6×	1.2k 1.5×	269 0.6×	373 0.9×	42	4.3k
Benjamin D. Hopkins United States	26	3.0k 0.9×	979 0.9×	940 1.2×	220 0.5×	417 1.0×	44	4.5k
Tarek Abbas United States	29	3.4k 1.0×	1.7k 1.5×	953 1.2×	300 0.6×	413 1.0×	41	4.5k
Yvonne Ottaviano United States	12	3.2k 0.9×	1.4k 1.2×	665 0.9×	638 1.4×	380 1.0×	21	4.5k
Yonghe Li United States	35	2.4k 0.7×	807 0.7×	715 0.9×	246 0.5×	574 1.4×	57	3.7k
Annamaria Biroccio Italy	41	3.7k 1.1×	1.3k 1.2×	679 0.9×	166 0.4×	191 0.5×	117	5.1k
Tim H.‐M. Huang United States	37	3.5k 1.0×	852 0.8×	1.0k 1.4×	584 1.3×	221 0.6×	118	4.7k
Jingxuan Pan China	38	2.7k 0.8×	1.0k 0.9×	795 1.0×	142 0.3×	256 0.6×	90	4.1k
Jörg Bäsecke Germany	22	3.0k 0.9×	1.2k 1.1×	669 0.9×	160 0.3×	266 0.7×	34	4.4k

Countries citing papers authored by Zhongmei Zhou

Since Specialization

Citations

This map shows the geographic impact of Zhongmei Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhongmei Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhongmei Zhou more than expected).

Fields of papers citing papers by Zhongmei Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhongmei Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhongmei Zhou. The network helps show where Zhongmei Zhou may publish in the future.

Co-authorship network of co-authors of Zhongmei Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Zhongmei Zhou. A scholar is included among the top collaborators of Zhongmei Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhongmei Zhou. Zhongmei Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Qianqian, Tingting Liang, Yu Xiong, et al.. (2025). Hsp70 incompletely disaggregates misfolded K488X-menin to promote tumourigenesis in a family with multiple endocrine neoplasia type 1. Cellular Signalling. 130. 111681–111681. 1 indexed citations

Liu, Rong, Min Bao, Zhongmei Zhou, et al.. (2022). STAMBPL1 promotes breast cancer cell resistance to cisplatin partially by stabilizing MKP-1 expression. Oncogene. 41(16). 2265–2274. 16 indexed citations

Jiang, Dewei, Ting Qiu, Siyuan Li, et al.. (2022). YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer. Cell Death and Differentiation. 29(6). 1283–1295. 54 indexed citations

Zhou, Zhongmei, et al.. (2019). Analysis of drug resistance of Klebsiella pneumonia isolated from different specimens in hospital. 7(1). 31–34. 1 indexed citations

Liang, Huichun, Xiao‐Jun Ji, Zhongmei Zhou, et al.. (2018). Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis. Oncogene. 37(15). 1961–1975. 109 indexed citations

Wu, Jing, Ye Ding, Zhongmei Zhou, et al.. (2016). A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5. Cancer Letters. 380(2). 393–402. 51 indexed citations

Zhou, Zhongmei, et al.. (2016). Gemcitabine-based polymer-drug conjugate for enhanced anticancer effect in colon cancer. International Journal of Pharmaceutics. 513(1-2). 564–571. 17 indexed citations

Ge, Fei, Wenlin Chen, Zhongmei Zhou, et al.. (2014). WWOX suppresses KLF5 expression and breast cancer cell growth.. PubMed. 26(5). 511–6. 5 indexed citations

Wang, Zehua, Zhi Nie, Wenlin Chen, et al.. (2013). RNF115/BCA2 E3 Ubiquitin Ligase Promotes Breast Cancer Cell Proliferation through Targeting p21Waf1/Cip1 for Ubiquitin-Mediated Degradation. Neoplasia. 15(9). 1028–1035. 28 indexed citations

10.

Xia, Houjun, Chunyan Wang, Wenlin Chen, et al.. (2013). Krüppel-like Factor 5 Transcription Factor Promotes Microsomal Prostaglandin E2 Synthase 1 Gene Transcription in Breast Cancer. Journal of Biological Chemistry. 288(37). 26731–26740. 39 indexed citations

11.

Zhi, Xu, Dong Zhao, Zehua Wang, et al.. (2012). E3 Ubiquitin Ligase RNF126 Promotes Cancer Cell Proliferation by Targeting the Tumor Suppressor p21 for Ubiquitin-Mediated Degradation. Cancer Research. 73(1). 385–394. 63 indexed citations

12.

Poon, Jiat Ling, Zhongmei Zhou, Jason N. Doctor, et al.. (2012). Quality of life in haemophilia A: Hemophilia Utilization Group Study Va (HUGS‐Va). Haemophilia. 18(5). 699–707. 58 indexed citations

13.

Zhou, Zhongmei, Joanne Wu, Judith Baker, et al.. (2011). Haemophilia Utilization Group Study – Part Va (HUGS Va): design, methods and baseline data. Haemophilia. 17(5). 729–736. 25 indexed citations

14.

Chen, Ceshi, Zhongmei Zhou, Christine E. Sheehan, et al.. (2009). Overexpression of WWP1 is associated with the estrogen receptor and insulin‐like growth factor receptor 1 in breast carcinoma. International Journal of Cancer. 124(12). 2829–2836. 39 indexed citations

15.

Chen, C, et al.. (2008). The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11. Oncogene. 27(54). 6845–6855. 52 indexed citations

16.

Zhou, Zhongmei, et al.. (2008). WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death and Differentiation. 15(12). 1941–1951. 129 indexed citations

17.

Zhou, Zhongmei, et al.. (2007). Assessment of apoptosis-inducing effects of docetaxel combined with the proteasome inhibitor PS-341 in human lung cancer cells. Cancer Biology & Therapy. 6(5). 749–754. 8 indexed citations

18.

Sun, Shi‐Yong, Zhongmei Zhou, Ruoxiang Wang, Haian Fu, & Fadlo R. Khuri. (2004). The farnesyltransferase inhibitor lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt. Cancer Biology & Therapy. 3(11). 1092–1098. 28 indexed citations

19.

Chen, Ceshi, Zhongmei Zhou, Xiaodong Sun, et al.. (2004). Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells. Gene. 330. 133–142. 37 indexed citations

20.

Lin, Tong-Yu, et al.. (1999). High dose ifosfamide, doxorubicin, dacarbazine and G-CSF for patients with metastatic or locally advanced soft tissue sarcoma. Chinese Journal of Cancer Research. 11(3). 200–203. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact